Inter HTA practices

WP10 - Guidance to support consistent HTA appraisal for orphan medicinal products (OMPs) HTA Appraisal Framework Suitable for Rare Disease Treatments K Facey1, A Whittal2, M Drummond2'3, S...

       Patient involvement in HTA:  What added value?          K.M. Facey          Health Economics and HTA, Institute of Health and Wellbeing,          University of Glasgow, Glasgow, UK        ...

Introduction to mini-HTA - a management and decision support tool for the hospital service Prepared by a project group under DACEHTA of the Danish National Board of Health with representatives from...

  Mapping of HTA national organizations, programs, and processes in EU Aim of the study The present study was undertaken at the request of the Directorate-General for Health and Food Safety...

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe Paweł Kawalec1*, Anna Sagan2,4 and Andrzej Pilc3 Orphanet Journal of Rare Diseases (2016) 11:122 ...

An up-to-date version of the Ukrainian National essential medicine list was compiled on the basis of  19th edition (April 2015) WHO Model List of Essential Medicines Full version of the WHO Model...

NICE was originally set up in 1999 as the National Institute for Clinical Excellence, a special health authority, to reduce variation in the availability and quality of NHS treatments and care. In...

The HTA Core Model® is a methodological framework for production and sharing of HTA information. The HTA Core Model® is a registered trademark. Please refer to the resources of EUnetHTA

In 2004, the European Commission and Council of Ministers targeted Health Technology Assessment (HTA) as “a political priority”, recognising “an urgent need for establishing a sustainable European...